Genetic Analysis AS

Price Chart

Risk-Adjusted Performance

Genetic Analysis AS (GEAN) Price Performance

Genetic Analysis AS (GEAN) trades on Nasdaq Stockholm in NOK. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at NOK0.63, down 8.70% from the previous close.

Over the past year, GEAN has traded between a low of NOK0.60 and a high of NOK2.12. The stock has lost 48.8% over this period. It is currently 70.3% below its 52-week high.

Genetic Analysis AS has a market capitalization of $46.01M.

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Collection Kit used for collection, transport, and storage of fecal specimens for nucleic acid analyses; and GA-map Covid-19 Fecal Test, a non-invasive test with an easy-to-use home sampling procedure. Further, it offers laboratory services; and bioinformatic analysis services. The company develops rapid microbiome-based PCR test. Genetic Analysis AS was founded in 2008 and is headquartered in Oslo, Norway.

Compare Genetic Analysis AS

Side-by-side comparison against top Healthcare peers.